Literature DB >> 7726313

Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients.

S E Arnold1, R E Gur, R M Shapiro, K R Fisher, P J Moberg, M R Gibney, R C Gur, P Blackwell, J Q Trojanowski.   

Abstract

OBJECTIVE: The purpose of this study was to characterize the neuropsychiatric profile of elderly patients with schizophrenia and establish a patient registry for prospective ante-mortem and post-mortem studies.
METHOD: Medical records of all chronically institutionalized patients in eight state hospitals who were over the age of 65 and had a chart diagnosis of schizophrenia (N = 528) were reviewed. Of the potential subjects, 192 were excluded because of clinical histories inconsistent with a diagnosis of schizophrenia, 56 because of insufficient information to establish a psychiatric diagnosis, and 122 because of family members' refusal to give consent for autopsy in the event of death. To date, 81 of the remaining 158 patients have undergone neuropsychiatric evaluation with standard assessment instruments.
RESULTS: Mini-Mental State scores of the 81 patients indicated severe dementia, and Functional Assessment Scale scores showed that patients required assistance with activities of daily living. All patients were rated as severely ill on the Brief Psychiatric Rating Scale. Ratings on the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms indicated a predominance of negative symptoms over positive. Of 30 patients who have died to date, research autopsies have been conducted on 26.
CONCLUSIONS: Establishing a well characterized, prospective patient registry for clinicopathologic studies of schizophrenia is feasible but labor intensive. Diagnosis of schizophrenia with a high degree of confidence can be achieved by means of detailed chart review and assessment of current neuropsychiatric functioning with standard rating instruments. These data provide a basis for correlations of clinicopathologic factors.

Entities:  

Mesh:

Year:  1995        PMID: 7726313     DOI: 10.1176/ajp.152.5.731

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  16 in total

1.  Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.

Authors:  Yong Chen; Sookhee Bang; Mary F McMullen; Hala Kazi; Konrad Talbot; Mei-Xuan Ho; Greg Carlson; Steven E Arnold; Wei-Yi Ong; Sangwon F Kim
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

Review 2.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

3.  The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay.

Authors:  Philip D Harvey; Abraham Reichenberg; Christopher R Bowie; Thomas L Patterson; Robert K Heaton
Journal:  Biol Psychiatry       Date:  2010-03-03       Impact factor: 13.382

4.  Dementia as a complication of schizophrenia.

Authors:  P J de Vries; W G Honer; P M Kemp; P J McKenna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

5.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

6.  Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.

Authors:  Glenn A Doyle; Richard C Crist; Emre T Karatas; Matthew J Hammond; Adam D Ewing; Thomas N Ferraro; Chang-Gyu Hahn; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2017-06-06       Impact factor: 7.853

7.  Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression.

Authors:  Junxia Tang; Robert P LeGros; Natalia Louneva; Lilly Yeh; Julia W Cohen; Chang-Gyu Hahn; Derek J Blake; Steven E Arnold; Konrad Talbot
Journal:  Hum Mol Genet       Date:  2009-07-19       Impact factor: 6.150

8.  Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias.

Authors:  Mark Yarchoan; Sharon X Xie; Mitchel A Kling; Jon B Toledo; David A Wolk; Edward B Lee; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Steven E Arnold
Journal:  Brain       Date:  2012-11-30       Impact factor: 13.501

Review 9.  Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia.

Authors:  Philip D Harvey; David A Loewenstein; Sara J Czaja
Journal:  Neurobiol Dis       Date:  2012-10-31       Impact factor: 5.996

10.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.